STERIS Raises Quarterly Dividend 9.5% to $0.69

STERIS plc raised its quarterly dividend 9.5% to $0.69 a share from $0.63. The shares traded ex-dividend on September 4, 2026, extending a record of regular increases in the healthcare company’s cash distribution.

Why the dividend changed

STERIS did not provide a specific reason for the increase in its brief dividend declaration. The operating backdrop, however, shows rising revenue and earnings, stable demand and continued spending on manufacturing capacity.

In its latest quarter, STERIS reported that revenue increased 7% to $1.5 billion and constant-currency organic revenue grew 6%. Reported diluted earnings were $2.04 a share, while adjusted earnings were $2.59 a share. Chief Executive Dan Carestio said the quarter reflected “stable underlying demand,” with Healthcare benefiting from share gains in consumables and services and solid capital-equipment order growth. The company left its fiscal 2027 revenue and earnings guidance unchanged. STERIS fiscal 2027 first-quarter results

The dividend increase also forms part of a broader capital-allocation program. In May, the board approved a new $1 billion share-repurchase authorization after fiscal 2026 revenue from continuing operations increased 9%. STERIS said free cash flow can be used for debt repayment, business growth, dividends and share repurchases. STERIS fiscal 2026 results

STERIS is simultaneously committing capital to expansion. The company plans to invest $600 million in a North Carolina manufacturing and distribution center for formulated chemistries used by healthcare and pharmaceutical customers. Management expects the project to expand capacity, accelerate innovation and consolidate work now performed in Missouri and Minnesota. STERIS manufacturing investment announcement

That evidence provides context for the board’s decision, but STERIS did not directly attribute the dividend increase to any single result, forecast or investment.

Dividend track record

STERIS called this its 21st consecutive year of dividend growth, a longer record than is apparent from some payment histories. The pattern in recent payments is a series of annual step-ups rather than irregular changes: the quarterly rate was $0.57 through June 2025, increased to $0.63 in September 2025 and remained there for the next two payments before reaching $0.69 in September 2026.

Full-year distributions rose from $1.54 in 2020 to $2.18 in 2024. The annual increases over that span were 7.8%, 8.4%, 10.0% and 10.1%, showing that the latest 9.5% increase is consistent with the recent pace. The five-year annualized dividend growth rate is 8.2%.

The 2025 entry totals $1.77 across three payments and is marked down 18.8%. That lower aggregate coincides with one fewer recorded payment, while the individual quarterly rate increased during the year. No prior annual cut is recorded.

Is the dividend covered?

The dividend consumes 31% of earnings. That is a relatively restrained payout, indicating that most earnings remain inside the company for capital spending, debt service, acquisitions, repurchases and other corporate needs.

SmarterDividends rates the dividend A, with a safety score of 93. That falls within the “very safe” range of 80-100 and indicates strong assessed capacity to sustain the distribution based on current financial measures. The grade describes coverage and financial resilience, not a guarantee that future dividends will remain unchanged.

Yield and valuation

STERIS has a forward dividend yield of 1.23%, below the Healthcare sector median of 1.80%. The shares therefore provide less current dividend income than the sector midpoint, while the company’s 21-year growth record and 9.5% latest increase are the more prominent features of its income profile.

At a share price of $209.70, SmarterDividends estimates fair value at $179.76 and assigns a “fair” valuation verdict. The company’s market value is $20.4 billion.

What to watch

The next quarterly report will show whether STERIS continues to meet its unchanged fiscal 2027 revenue and earnings guidance while funding both the higher dividend and its manufacturing program. Particular points include Healthcare consumables and service growth, capital-equipment orders and the effect of tariffs and inflation on operating income.

Cash deployment also warrants attention. After announcing the North Carolina project, STERIS increased expected capital expenditures to approximately $450 million from $375 million and reduced expected free cash flow to approximately $800 million from $850 million. The related restructuring is expected to continue through fiscal 2030. Investors can monitor those outlays alongside share repurchases and subsequent quarterly dividend declarations to assess how management balances expansion with cash returns.